Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Hashimoto Thyroiditis | Review

Intestinal microbiota regulates the gut-thyroid axis: the new dawn of improving Hashimoto thyroiditis

Authors: Xiaxin Zhu, Chi Zhang, Shuyan Feng, Ruonan He, Shuo Zhang

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Intestinal microbiota plays an indispensable role in the host's innate immune system, which may be related to the occurrence of many autoimmune diseases. Hashimoto thyroiditis (HT) is one of the most common autoimmune diseases, and there is plenty of evidence indicating that HT may be related to genetics and environmental triggers, but the specific mechanism has not been proven clearly. Significantly, the composition and abundance of intestinal microbiota in patients with HT have an obvious difference. This phenomenon led us to think about whether intestinal microbiota can affect the progress of HT through some mechanisms. By summarizing the potential mechanism of intestinal microflora in regulating Hashimoto thyroiditis, this article explores the possibility of improving HT by regulating intestinal microbiota and summarizes relevant biomarkers as therapeutic targets, which provide new ideas for the clinical diagnosis and treatment of Hashimoto thyroiditis.
Literature
1.
Ralli M, et al. Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649.PubMedCrossRef
2.
Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med. 2022;132(3):16222.PubMedPubMedCentral
3.
McLeod DSA, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252–65.PubMedCrossRef
4.
Ott J, et al. The incidence of lymphocytic thyroid infiltration and Hashimoto’s thyroiditis increased in patients operated for benign goiter over a 31-year period. Virchows Archiv Int J Pathol. 2011;459(3):277–81.CrossRef
5.
Ragusa F, et al. Hashimotos’ thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101367.PubMedCrossRef
6.
7.
Teng W, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354(26):2783–93.PubMedCrossRef
8.
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4–5):391–7.PubMedCrossRef
9.
10.
11.
12.
Virili C, et al. Gut microbiota and Hashimoto’s thyroiditis. Rev Endocr Metab Disord. 2018;19(4):293–300.PubMedCrossRef
13.
Suzuki K, et al. GALT: organization and dynamics leading to IgA synthesis. Adv Immunol. 2010;107:153–85.PubMedCrossRef
14.
Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10(3):159–69.PubMedCrossRef
15.
Kamada N, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–35.PubMedCrossRef
16.
Mallon P, et al. Probiotics for induction of remission in ulcerative colitis. In: The Cochrane database of systematic reviews, no. 4; 2007. p. CD005573.
17.
Simon E, et al. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients. 2021;13(6):2112.PubMedPubMedCentralCrossRef
18.
Liu Y, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology (Baltimore, MD). 2020;71(6):2050–66.PubMedCrossRef
19.
20.
Zaiss MM, et al. The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(4):224–37.PubMedCrossRef
21.
Choi S-C, et al. Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice. Sci Transl Med. 2020;12(551):eaax2220.
22.
Shin NR, et al. Chemically or surgically induced thyroid dysfunction altered gut microbiota in rat models. FASEB J. 2020;34(6):8686–701.PubMedCrossRef
23.
Su X, et al. Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. Clin Sci (Lond, Engl: 1979). 2020;134(12):1521–35.CrossRef
24.
Cayres LCdF, et al. Detection of alterations in the gut microbiota and intestinal permeability in patients with Hashimoto thyroiditis. Front Immunol. 2021;12:579140.PubMedPubMedCentralCrossRef
25.
26.
Virili C, Centanni M. “With a little help from my friends”—the role of microbiota in thyroid hormone metabolism and enterohepatic recycling. Mol Cell Endocrinol. 2017;458:39–43.PubMedCrossRef
27.
Tomasello G, et al. Dysmicrobism, inflammatory bowel disease and thyroiditis: analysis of the literature. J Biol Regul Homeost Agents. 2015;29(2):265–72.PubMed
28.
Guo Q, et al. Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis. Front Immunol. 2018;9:1197.PubMedPubMedCentralCrossRef
29.
Fenneman AC, et al. Gut microbiota and metabolites in the pathogenesis of endocrine disease. Biochem Soc Trans. 2020;48(3):915–31.PubMedCrossRef
30.
Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079–89.PubMedCrossRef
31.
Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14(1):20–32.PubMedCrossRef
32.
33.
Fujisaka S, Watanabe Y, Tobe K. The gut microbiome: a core regulator of metabolism. J Endocrinol. 2022;256(3):e220111.
34.
Gong B, et al. Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis. Front Endocrinol. 2021;12:774362.CrossRef
35.
Zhao F, et al. Alterations of the gut microbiota in Hashimoto’s thyroiditis patients. Thyroid. 2018;28(2):175–86.PubMedCrossRef
36.
Ishaq HM, et al. Molecular estimation of alteration in intestinal microbial composition in Hashimoto’s thyroiditis patients. Biomed Pharmacother. 2017;95:865–74.PubMedCrossRef
37.
38.
Cornejo-Pareja I, et al. Differential microbial pattern description in subjects with autoimmune-based thyroid diseases: a pilot study. J Person Med. 2020;10(4):192.CrossRef
39.
Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms. 2020;8(11):1715.PubMedPubMedCentralCrossRef
40.
Fröhlich E, Wahl R. Microbiota and thyroid interaction in health and disease. Trends Endocrinol Metab. 2019;30(8):479–90.PubMedCrossRef
41.
Liu S, et al. The composition of gut microbiota in patients bearing Hashimoto’s thyroiditis with euthyroidism and hypothyroidism. Int J Endocrinol. 2020;2020:5036959.PubMedPubMedCentralCrossRef
42.
43.
Medzhitov R, Janeway C. The Toll receptor family and microbial recognition. Trends Microbiol. 2000;8(10):452–6.PubMedCrossRef
44.
45.
46.
47.
48.
49.
Satoh-Takayama N, et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008;29(6):958–70.PubMedCrossRef
50.
Sanos SL, et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol. 2009;10(1):83–91.PubMedCrossRef
51.
Kunii J, et al. Commensal bacteria promote migration of mast cells into the intestine. Immunobiology. 2011;216(6):692–7.PubMedCrossRef
52.
Bischoff SC, Krämer S. Human mast cells, bacteria, and intestinal immunity. Immunol Rev. 2007;217:329–37.PubMedCrossRef
53.
54.
Virili C, Stramazzo I, Centanni M. Gut microbiome and thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2021;35(3):101506.PubMedCrossRef
55.
Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 2010;107(27):12204–9.ADSPubMedPubMedCentralCrossRef
56.
Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283–97.PubMedCrossRef
57.
Cekanaviciute E, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA. 2017;114(40):10713–8.ADSPubMedPubMedCentralCrossRef
58.
Ostman S, et al. Impaired regulatory T cell function in germ-free mice. Eur J Immunol. 2006;36(9):2336–46.PubMedCrossRef
59.
60.
61.
Telesford KM, et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes. 2015;6(4):234–42.PubMedPubMedCentralCrossRef
62.
Mazmanian SK, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–18.PubMedCrossRef
63.
Wang Y, et al. A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes. 2014;5(4):552–61.PubMedCrossRef
64.
Mørland B, Midtvedt T. Phagocytosis, peritoneal influx, and enzyme activities in peritoneal macrophages from germfree, conventional, and ex-germfree mice. Infect Immun. 1984;44(3):750–2.PubMedPubMedCentralCrossRef
65.
Zhang W, et al. Lactic acid bacterial colonization and human rotavirus infection influence distribution and frequencies of monocytes/macrophages and dendritic cells in neonatal gnotobiotic pigs. Vet Immunol Immunopathol. 2008;121(3–4):222–31.PubMedCrossRef
66.
Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord. 2016;17(4):485–98.PubMedCrossRef
67.
Sousa MdAC, Paraná R, Andrade LJdO. Sequence similarity between thyroid self-protein and hepatitis C virus polyprotein: possible triggering mechanism of autoimmune thyroiditis. Arq Gastroenterol. 2016;53(3):185–91.ADSPubMedCrossRef
68.
Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–11.PubMedCrossRef
69.
Kiseleva EP, et al. The role of components of Bifidobacterium and Lactobacillus in pathogenesis and serologic diagnosis of autoimmune thyroid diseases. Benef Microbes. 2011;2(2):139–54.PubMedCrossRef
70.
Masala S, et al. Lack of humoral response against Helicobacter pylori peptides homologous to human ZnT8 in Hashimoto’s thyroiditis patients. J Infect Dev Ctries. 2015;9(6):631–4.PubMedCrossRef
71.
Benvenga S, et al. Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs to HLA-DR molecules and T-cell receptor. Thyroid. 2006;16(3):225–36.PubMedCrossRef
72.
73.
74.
Arata N, et al. By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin Immunol (Orlando, Fla). 2006;121(1):108–17.CrossRef
75.
76.
Thrasyvoulides A, Lymberi P. Evidence for intramolecular B-cell epitope spreading during experimental immunization with an immunogenic thyroglobulin peptide. Clin Exp Immunol. 2003;132(3):401–7.PubMedPubMedCentralCrossRef
77.
Lerner A, Aminov R, Matthias T. Dysbiosis may trigger autoimmune diseases via inappropriate post-translational modification of host proteins. Front Microbiol. 2016;7:84.PubMedPubMedCentralCrossRef
78.
Muller S, Radic M. Citrullinated autoantigens: from diagnostic markers to pathogenetic mechanisms. Clin Rev Allergy Immunol. 2015;49(2):232–9.PubMedCrossRef
79.
Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science (New York, NY). 2005;307(5717):1920–5.ADSPubMedCrossRef
80.
Natividad JMM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res. 2013;69(1):42–51.PubMedCrossRef
81.
Meslin JC, Fontaine N, Andrieux C. Variation of mucin distribution in the rat intestine, caecum and colon: effect of the bacterial flora. Comp Biochem Physiol Part A Mol Integr Physiol. 1999;123(3):235–9.CrossRef
82.
Čaja F, et al. Immune activation by microbiome shapes the colon mucosa: Comparison between healthy rat mucosa under conventional and germ-free conditions. J Immunotoxicol. 2021;18(1):37–49.PubMedCrossRef
83.
84.
Demir E, et al. The relationship between elevated plasma zonulin levels and Hashimoto’s thyroiditis. Turk J Med Sci. 2022;52(3):605–12.PubMedCrossRef
85.
Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151–75.PubMedCrossRef
86.
Manfredo Vieira S, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science (New York, NY). 2018;359(6380):1156–61.ADSPubMedCrossRef
87.
88.
89.
Yang L, et al. Impaired autophagy in intestinal epithelial cells alters gut microbiota and host immune responses. Appl Environ Microbiol. 2018;84(18):e00880–18.
90.
Zhang C, et al. Inhibition of autophagic degradation process contributes to claudin-2 expression increase and epithelial tight junction dysfunction in TNF-α treated cell monolayers. Int J Mol Sci. 2017;18(1):157.PubMedPubMedCentralCrossRef
91.
Hu C-AA, et al. Autophagy and tight junction proteins in the intestine and intestinal diseases. Anim Nutr (Zhongguo Xu Mu Shou Yi Xue Hui). 2015;1(3):123–7.
92.
93.
Foerster EG, et al. How autophagy controls the intestinal epithelial barrier. Autophagy. 2022;18(1):86–103.PubMedCrossRef
94.
95.
Konca Degertekin C, et al. Circulating Th17 cytokine levels are altered in Hashimoto’s thyroiditis. Cytokine. 2016;80:13–7.PubMedCrossRef
96.
97.
Zheng T, et al. Increased Interleukin-23 in Hashimoto’s thyroiditis disease induces autophagy suppression and reactive oxygen species accumulation. Front Immunol. 2018;9:96.PubMedPubMedCentralCrossRef
98.
Lu Q, et al. Caveolin-1 regulates autophagy activity in thyroid follicular cells and is involved in Hashimoto’s thyroiditis disease. Endocr J. 2018;65(9):893–901.PubMedCrossRef
99.
100.
101.
Zhao R, Zhou H, Su SB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol. 2013;17(3):658–69.PubMedCrossRef
102.
Papadakis KA, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol (Baltimore, Md: 1950). 2005;174(8):4985–90.CrossRef
103.
Lalor SJ, et al. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol (Baltimore, Md: 1950). 2011;186(10):5738–48.CrossRef
104.
Shao S, et al. Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis. Pharmacol Ther. 2021;227:107880.PubMedCrossRef
105.
106.
Kayagaki N, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (New York, NY). 2013;341(6151):1246–9.ADSPubMedCrossRef
107.
Jiang W, et al. The relationships between the gut microbiota and its metabolites with thyroid diseases. Front Endocrinol. 2022;13:943408.CrossRef
108.
Brown AJ, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312–9.PubMedCrossRef
109.
Aoyama M, Kotani J, Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition (Burbank, Los Angeles County, Calif). 2010;26(6):653–61.PubMedCrossRef
110.
111.
He J, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356.PubMedPubMedCentralCrossRef
112.
Chang PV, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 2014;111(6):2247–52.ADSPubMedPubMedCentralCrossRef
113.
Macia L, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6:6734.ADSPubMedCrossRef
114.
115.
Pan X, et al. Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms. Br J Pharmacol. 2019;176(23):4446–61.PubMedPubMedCentralCrossRef
116.
Meng S, et al. Short-chain fatty acids and thyroid hormone interact in regulating enterocyte gene transcription. Surgery. 1999;126(2):293–8.PubMedCrossRef
117.
118.
Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–37.PubMedCrossRef
119.
Song X, et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature. 2020;577(7790):410–5.PubMedCrossRef
120.
Zhang X, et al. Trimethylamine-N-oxide promotes vascular calcification through activation of NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome and NF-κB (nuclear factor κB) signals. Arterioscler Thromb Vasc Biol. 2020;40(3):751–65.PubMedCrossRef
121.
122.
Nicola JP, et al. NF-kappaB p65 subunit mediates lipopolysaccharide-induced Na(+)/I(-) symporter gene expression by involving functional interaction with the paired domain transcription factor Pax8. Mol Endocrinol (Baltimore, Md). 2010;24(9):1846–62.CrossRef
123.
Jin B, Wang S, Fan Z. Pathogenesis markers of Hashimoto’s disease-a mini review. Front Biosci (Landmark Edition). 2022;27(10):297.CrossRef
124.
125.
Liu J, et al. Excessive iodine promotes pyroptosis of thyroid follicular epithelial cells in Hashimoto’s thyroiditis through the ROS-NF-κB-NLRP3 pathway. Front Endocrinol. 2019;10:778.CrossRef
126.
Duntas LH. The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res. 2015;47(10):721–6.PubMedCrossRef
127.
Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78(2):155–64.CrossRef
128.
Calomme M, et al. Seleno-lactobacillus. An organic selenium source. Biol Trace Elem Res. 1995;47(1–3):379–83.PubMedCrossRef
129.
130.
Zimmermann MB. The influence of iron status on iodine utilization and thyroid function. Annu Rev Nutr. 2006;26:367–89.PubMedCrossRef
131.
Constante M, et al. Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2017;23(5):753–66.PubMedCrossRef
132.
Chieppa M, Giannelli G. Immune cells and microbiota response to iron starvation. Front Med. 2018;5:109.CrossRef
133.
Bouglé D, et al. Influence of short-chain fatty acids on iron absorption by proximal colon. Scand J Gastroenterol. 2002;37(9):1008–11.PubMedCrossRef
134.
Dostal A, et al. Low iron availability in continuous in vitro colonic fermentations induces strong dysbiosis of the child gut microbial consortium and a decrease in main metabolites. FEMS Microbiol Ecol. 2013;83(1):161–75.PubMedCrossRef
135.
Yilmaz B, Li H. Gut microbiota and iron: the crucial actors in health and disease. Pharmaceuticals (Basel, Switzerland). 2018;11(4):98.PubMedCrossRef
136.
137.
Severo JS, et al. The role of zinc in thyroid hormones metabolism. Int J Vitam Nutr Res. 2019;89(1–2):80–8.PubMedCrossRef
138.
Rutgers M, et al. Enterohepatic circulation of triiodothyronine (T3) in rats: importance of the microflora for the liberation and reabsorption of T3 from biliary T3 conjugates. Endocrinology. 1989;125(6):2822–30.PubMedCrossRef
139.
Nguyen TT, et al. 5’- and 5-deiodinase activities in adult rat cecum and large bowel contents inhibited by intestinal microflora. Am J Physiol. 1993;265(3 Pt 1):E521–4.PubMed
140.
Spaggiari G, et al. Probiotics ingestion does not directly affect thyroid hormonal parameters in hypothyroid patients on levothyroxine treatment. Front Endocrinol. 2017;8:316.CrossRef
141.
142.
Lauritano EC, et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab. 2007;92(11):4180–4.PubMedCrossRef
143.
Gunsar F, et al. Effect of hypo- and hyperthyroidism on gastric myoelectrical activity. Dig Dis Sci. 2003;48(4):706–12.PubMedCrossRef
144.
Fukunaga K. Refractory gastrointestinal bleeding treated with thyroid hormone replacement. J Clin Gastroenterol. 2001;33(2):145–7.PubMedCrossRef
145.
146.
Rotondi Aufiero V, Fasano A, Mazzarella G. Non-celiac gluten sensitivity: how its gut immune activation and potential dietary management differ from celiac disease. Mol Nutr Food Res. 2018;62(9):e1700854.PubMedCrossRef
147.
Cuan-Baltazar Y, Soto-Vega E. Microorganisms associated to thyroid autoimmunity. Autoimmun Rev. 2020;19(9):102614.PubMedCrossRef
148.
Cellini M, et al. Hashimoto’s thyroiditis and autoimmune gastritis. Front Endocrinol. 2017;8:92.CrossRef
149.
Shi W-J, et al. Associations of helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid. 2013;23(10):1294–300.PubMedCrossRef
150.
Checchi S, et al. Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. Thyroid. 2010;20(12):1385–9.PubMedCrossRef
151.
Nicolaou A, et al. Predictive value of gastrin levels for the diagnosis of gastric enterochromaffin-like cell hyperplasia in patients with Hashimoto’s thyroiditis. Neuroendocrinology. 2014;99(2):118–22.PubMedCrossRef
152.
Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078.PubMedPubMedCentralCrossRef
153.
Shah SC, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925–34.PubMedCrossRef
154.
Lauritano EC, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13(2):111–6.PubMed
155.
Kim M-S, et al. The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci. 2013;58(6):1676–82.PubMedCrossRef
156.
Xu D, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484.PubMedCrossRef
157.
Maccaferri S, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65(12):2556–65.PubMedCrossRef
158.
Lauritano EC, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31–5.PubMedCrossRef
159.
Scarpellini E, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25(7):781–6.PubMedCrossRef
160.
161.
162.
Huo D, et al. Probiotic Bifidobacterium longum supplied with methimazole improved the thyroid function of Graves’ disease patients through the gut-thyroid axis. Commun Biol. 2021;4(1):1046.PubMedPubMedCentralCrossRef
163.
Williams EA, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29(1):97–103.PubMedCrossRef
164.
165.
Talebi S, et al. The effects of synbiotic supplementation on thyroid function and inflammation in hypothyroid patients: a randomized, double-blind, placebo-controlled trial. Complement Ther Med. 2020;48:102234.PubMedCrossRef
166.
167.
168.
Zheng L, et al. Fecal microbiota transplantation in the metabolic diseases: current status and perspectives. World J Gastroenterol. 2022;28(23):2546–60.PubMedPubMedCentralCrossRef
169.
van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.PubMedCrossRef
170.
171.
David LA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.ADSPubMedCrossRef
172.
173.
174.
Konijeti GG, et al. Efficacy of the autoimmune protocol diet for inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(11):2054–60.PubMedCrossRef
175.
Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for Hashimoto’s thyroiditis. Cureus. 2019;11(4):e4556.PubMedPubMedCentral
176.
Ruggeri RM, et al. Influence of dietary habits on oxidative stress markers in Hashimoto’s thyroiditis. Thyroid. 2021;31(1):706–7.PubMedCrossRef
177.
Virili C, et al. Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab. 2012;97(3):E419–22.PubMedCrossRef
178.
Krysiak R, Szkróbka W, Okopień B. The effect of gluten-free diet on thyroid autoimmunity in drug-naïve women with Hashimoto’s thyroiditis: a pilot study. Exp Clin Endocrinol Diabetes. 2019;127(7):417–22.PubMedCrossRef
179.
Mikulska AA, et al. Metabolic characteristics of Hashimoto’s thyroiditis patients and the role of microelements and diet in the disease management-an overview. Int J Mol Sci. 2022;23(12):6580.PubMedPubMedCentralCrossRef
180.
181.
Chahardoli R, et al. Can supplementation with vitamin D modify thyroid autoantibodies (anti-TPO Ab, Anti-Tg Ab) and thyroid profile (T3, T4, TSH) in Hashimoto’s thyroiditis? A double blind, randomized clinical trial. Horm Metab Res. 2019;51(5):296–301.PubMedCrossRef
182.
Fasano A, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet (London, England). 2000;355(9214):1518–9.PubMedCrossRef
183.
Tripathi A, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799–804.ADSPubMedPubMedCentralCrossRef
184.
Zheng D, et al. Elevated levels of circulating biomarkers related to leaky gut syndrome and bacterial translocation are associated with Graves’ disease. Front Endocrinol. 2021;12:796212.CrossRef
185.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26.PubMedCrossRef
186.
Kawashima A, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions. Thyroid. 2013;23(4):477–87.PubMedPubMedCentralCrossRef
187.
Liu Z, et al. Thyrocyte interleukin-18 expression is up-regulated by interferon-γ and may contribute to thyroid destruction in Hashimoto’s thyroiditis. Int J Exp Pathol. 2010;91(5):420–5.PubMedPubMedCentralCrossRef
188.
Seo S-U, et al. Distinct commensals induce interleukin-1β via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity. 2015;42(4):744–55.PubMedPubMedCentralCrossRef
189.
190.
Furusawa Y, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50.ADSPubMedCrossRef
191.
Nicola JP, et al. Functional toll-like receptor 4 conferring lipopolysaccharide responsiveness is expressed in thyroid cells. Endocrinology. 2009;150(1):500–8.PubMedCrossRef
192.
Sánchez E, et al. Contribution of TNF-alpha and nuclear factor-kappaB signaling to type 2 iodothyronine deiodinase activation in the mediobasal hypothalamus after lipopolysaccharide administration. Endocrinology. 2010;151(8):3827–35.PubMedPubMedCentralCrossRef
193.
Baur A, et al. Effects of proinflammatory cytokines on anterior pituitary 5’-deiodinase type I and type II. J Endocrinol. 2000;167(3):505–15.PubMedCrossRef
194.
Doden H, et al. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018;84(10):e00235–18.
195.
196.
Liu J, et al. Serum metabolomic patterns in patients with autoimmune thyroid disease. Endocr Pract. 2020;26(1):82–96.PubMedCrossRef
197.
Lu X, et al. Changes in histone H3 lysine 4 trimethylation in Hashimoto’s thyroiditis. Arch Med Sci AMS. 2022;18(1):153–63.MathSciNetPubMed
198.
Zhao S, et al. H3K4 methylation regulates LPS-induced proinflammatory cytokine expression and release in macrophages. Shock (Augusta, Ga). 2019;51(3):401–6.PubMedCrossRef
199.
Bassi V, et al. Identification of a correlation between Helicobacter pylori infection and Graves’ disease. Helicobacter. 2010;15(6):558–62.PubMedCrossRef
Metadata
Title
Intestinal microbiota regulates the gut-thyroid axis: the new dawn of improving Hashimoto thyroiditis
Authors
Xiaxin Zhu
Chi Zhang
Shuyan Feng
Ruonan He
Shuo Zhang
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-024-01304-4

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue

Research

Risk factors for severe COVID-19 infection and the impact of COVID-19 infection on disease progression among patients with AAV

Review

Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications

Research

Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma

Research

Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)

Research

Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study

Research

Helios characterized circulating follicular helper T cells with enhanced functional phenotypes and was increased in patients with systemic lupus erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits